A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). | MicrobiomeTrials
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2021-09-09Est. Completion: 2024-12-17
Enrollment target: 27 participants
Locations
Children Hospital LA, Los Angeles, California, United States
University of California - San Francisco, San Francisco, California, United States
Medstar Georgetown University Hospital, Washington D.C., District of Columbia, United States
Ochsner Hospital for Children, New Orleans, Louisiana, United States
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Texas Children's Hospital, Houston, Texas, United States
Seattle Children's Hospital, Seattle, Washington, United States